Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Altria Group (MO) Misses Q2 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Piper Jaffray Cuts Price Target as Insys Therapeutics' (INSY) Guides to a Decline in Subsys Sales
February 24, 2016 10:20 AM ESTPiper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00), following the company's 4Q earnings report. Insys reported adjusted diluted EPS of $0.36 on revenues of $91M, in-line with Street estimates. INSY is guiding to a sequential decline in Subsys sales in 1Q16, driven in significant part by the company no longer contracting with OptumRx. This is... More
Insys Therapeutics (INSY) Tops Q4 EPS by 7c
February 23, 2016 6:50 AM ESTInsys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.36, $0.07 better than the analyst estimate of $0.29. Revenue for the quarter came in at $91.1 million versus the consensus estimate of $91.04 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
... More